The Cost of Cancer Care at the End of Life: Implications for Centers for Medicare and Medicaid Services and for Radiation Oncology.
暂无分享,去创建一个
[1] H. Sandler,et al. Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life. , 2022, International journal of radiation oncology, biology, physics.
[2] T. Bathala,et al. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-In Phase of the Randomized Basket Trial EXTEND. , 2022, International journal of radiation oncology, biology, physics.
[3] B. Yaremko,et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes. , 2022, International journal of radiation oncology, biology, physics.
[4] E. Bruera,et al. Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital , 2022, Supportive Care in Cancer.
[5] S. Loi,et al. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. , 2021, European urology.
[6] S. Vinod,et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.
[7] E. Goetghebeur,et al. PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial , 2020, BMC Cancer.
[8] B. Yaremko,et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.
[9] S. Gilbertson-White,et al. Immune Checkpoint Inhibitor Use Near the End of Life: A Single-Center Retrospective Study. , 2019, Journal of palliative medicine.
[10] A. Kishan,et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease , 2019, BMC Cancer.
[11] V. Khoo,et al. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II , 2018, BMC Cancer.
[12] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[13] Ehud Mendel,et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.
[14] R. Schilsky,et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.